Samsung Bioepis and Merck Launch Herceptin (trasuzumab) Biosimilar Ontruzant® in U.S.
This week, Samsung Bioepis announced the U.S. launch of Ontruzant® (trastuzumab-dttb), a biosimilar of Genentech’s Herceptin (trasuzumab). Ontruzant® will be marketed and distributed in the U.S. by Merck. This launch represents Samsung Bioepis’s first oncology biosimilar in the U.S. market. Genentech’s Herceptin is a monoclonal antibody used to treat breast cancer and metastatic stomach cancer, first approved in 1998. Genentech tried to block the market entry of Ontruzant® by suing for patent infringement, but Samsung Bioepis and Genentech reached a settlement in June 2019.